Life Sciences

  • March 17, 2026

    NeoGenomics Beats Investor Suit Over Growth Driver Claims

    Cancer diagnostics company NeoGenomics Inc. no longer faces a proposed investor class action alleging it mischaracterized its growth drivers, including by failing to disclose that a rainmaking unit potentially ran afoul of anti-kickback laws, after a Manhattan federal judge held the suit failed to show the company had intentionally misled the markets. 

  • March 17, 2026

    9th Circ. Backs Rare FCA Theory In Huge Drug Prices Program

    In a novel and potentially far-reaching decision, the Ninth Circuit on Tuesday revived a major hospital chain's False Claims Act suit accusing large pharmaceutical companies of massive overcharges in a prominent drug discount program where pricing disputes are common.

  • March 17, 2026

    Bard And AngioDynamics Resolve 11-Year Patent Dispute

    A Delaware federal judge on Tuesday closed the book on a vascular port patent dispute between C.R. Bard and AngioDynamics that had been pending for over 11 years, citing a settlement after the Federal Circuit invalidated Bard patents that a jury said AngioDynamics infringed.

  • March 17, 2026

    Dr. Oz Claims Florida Also Has Healthcare Fraud Problem

    Dr. Mehmet Oz, the administrator for the Centers for Medicare & Medicaid Services, announced Tuesday that he is taking his efforts to combat healthcare-related fraud to Florida, where he says millions of dollars have been wasted on schemes involving durable medical equipment.

  • March 17, 2026

    Geico Keeps RICO, Fraud Claims In NY No-Fault Billing Suit

    Two New York companies must face the majority of claims in Geico's suit alleging they exploited the state's no-fault insurance laws by fraudulently billing Geico more than $2.7 million for unnecessary durable medical equipment, a federal judge ruled Tuesday.

  • March 17, 2026

    Bipartisan Bill To Waive $100K H-1B Fee Gets AMA Backing

    Medical organizations and a bipartisan group of lawmakers are backing federal legislation introduced Tuesday that would exempt physicians and other healthcare workers from the Trump administration's $100,000 fee on H-1B visas.

  • March 17, 2026

    Edwards Beats Heart Valve IP Suit Just Before Trial

    A Delaware federal judge has ruled in favor of Edwards Lifesciences Corp. in a patent infringement suit brought against it by rival Aortic Innovations LLC, finding that the term "frame" as it appears in the patent claims lacks written description.

  • March 17, 2026

    Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033

    Specialty drugmaker Fennec Pharmaceuticals has jointly announced with Indian multinational pharmaceutical company Cipla Ltd. that they had reached an agreement to settle patent infringement litigation in exchange for Cipla delaying the manufacture of a generic pediatric cancer drug until 2033.

  • March 17, 2026

    Alcon Drops $430M Lensar Deal Under Pressure From FTC

    Swiss eye care company Alcon Inc. has abandoned its planned purchase of a Florida-based maker of laser treatments for cataracts, Lensar Inc., after the Federal Trade Commission threatened to block the $430 million deal.

  • March 17, 2026

    WTO Must Extend Digital Trade Protections, Lawmakers Told

    The World Trade Organization's moratorium on digital trade measures must be extended and its scope strengthened in support of U.S. business interests, experts testifying before the U.S. House's trade panel told lawmakers Tuesday.

  • March 17, 2026

    Drug Developer GNQ To Go Public Via $500M SPAC Deal

    Techbio company GNQ Insilico has announced plans to go public by merging with special-purpose acquisition company IB Acquisition Corp. in a deal that values it at $500 million and was built by four law firms.

  • March 17, 2026

    McGuireWoods Adds Former CDC Scientist From McDermott

    McGuireWoods LLP said Tuesday that it has hired a former Centers for Disease Control and Prevention scientist from McDermott Will & Schulte LLP, touting his background as a microbiologist and his history advising healthcare clients.

  • March 17, 2026

    Fenwick Healthcare Regulatory Atty Rejoins Latham In LA

    Latham & Watkins LLP is boosting its healthcare team, announcing Monday it is welcoming back a Fenwick & West LLP healthcare regulatory expert as a partner in its Los Angeles office.

  • March 16, 2026

    1st Circ. Affirms Block Of Trump's 'Unprecedented' Aid Freeze

    The First Circuit on Monday mostly upheld a lower court's order blocking the Trump administration from enacting a "sweeping and unprecedented categorical 'freeze' of federal financial assistance," ruling that the states involved in the suit will likely successfully show that the federal government acted arbitrarily and capriciously.

  • March 16, 2026

    Judge Tosses Kaiser Whistleblowers' Claims After $556M Deal

    A California federal court on Monday officially dismissed False Claims Act lawsuits from the federal government and three people alleging that Kaiser Permanente affiliates engaged in Medicare fraud, on the heels of Kaiser's $556 million settlement reached in January.

  • March 16, 2026

    Lannett Investors Seek Final OK Of $5.8M Price-Fix Probe Suit

    Former executives of pharmaceutical company Lannett Inc. and a class of investors have asked a Pennsylvania federal court to grant final approval to their $5.8 million deal to end claims the company and its leadership misled about Lannett's links to allegations of industrywide price-fixing in the market for generic drugs.

  • March 16, 2026

    J&J's Lack Of Malice Gets $966M Talc Verdict Cut To $16M

    A California state judge slashed $950 million in punitive damages from a $966 million jury verdict against Johnson & Johnson on Friday in a lawsuit involving an 88-year-old woman who died of mesothelioma, saying the estate's counsel failed to sufficiently show the pharmaceutical giant acted maliciously.

  • March 16, 2026

    Medtronic Seeks To Ax 'Extreme Outlier' $382M Antitrust Loss

    Medtronic has urged a California federal judge to scrap its nearly $382 million trial loss to rival Applied Medical over Medtronic's bundling practices that a jury found suppressed competition for advanced bipolar devices, arguing the verdict is an "extreme outlier" in antitrust law that can't survive.

  • March 16, 2026

    Amgen And Sanofi End Repatha IP Fight Heard By Justices

    Amgen Inc. and Sanofi have settled patent litigation over competing cholesterol drugs Repatha and Praluent, more than two years after they dueled at the U.S. Supreme Court, Sanofi confirmed Monday.

  • March 16, 2026

    Italy's Amplifon Buying Danish Hearing Device Biz For $2.6B

    Italy's Amplifon said Monday it has agreed to acquire the hearing device business of Denmark's GN Store Nord in a deal valuing the unit at about €2.3 billion ($2.6 billion), in a move aimed at creating a vertically integrated global leader in audiology.

  • March 16, 2026

    HHS' Childhood Vaccine Policy Changes Put On Ice

    A Massachusetts federal judge on Monday blocked the Trump administration's modified childhood vaccine schedule and put all decisions made by Health Secretary Robert F. Kennedy Jr.'s federal vaccine policy committee on hold, finding they veered sharply from normal procedure and likely violated the law.

  • March 16, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court's docket last week featured disputes including an $83.75 million settlement tied to a renewable energy merger, fraud claims in a fertilizer company acquisition and a developer's fight for control of a major Philadelphia redevelopment project.

  • March 13, 2026

    AIG Policy Excludes $150M Pollution Coverage, 7th Circ. Finds

    A Seventh Circuit panel on Friday ruled an AIG unit has no duty to cover $150 million in legal costs for Sterigenics and its former parent company following input from the Illinois Supreme Court on how to apply a pollution exclusion in the relevant policy.

  • March 13, 2026

    Maryland Bros. Get Prison For HIV Drug Fraud Scheme

    A Florida federal judge on Friday sentenced two Maryland brothers to prison for their roles in a fraudulent medication scheme that involved selling misbranded HIV drugs with fake tracing documents to pharmacies and patients. 

  • March 13, 2026

    She Has A Point: Finnegan's Cora Holt

    Cora Holt, a partner at Finnegan Henderson Farabow Garrett & Dunner LLP in Washington, D.C., has a "do your job" attitude and "getting the stuff done" approach to litigation that earned plaudits from Kassie Helm, co-chair of Dechert LLP, who praised Holt for her work as part of a Law360 series celebrating women litigators.

Expert Analysis

  • New Drug Ad Regs Could Lead To A Less Informed Public

    Author Photo

    A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.

  • Series

    Preaching Makes Me A Better Lawyer

    Author Photo

    Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.

  • A Look At Middlemen Fees In 340B Drug Discount Program

    Author Photo

    A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.

  • How Large Patent Damages Awards Actually Play Out

    Author Photo

    Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.

  • Series

    Law School's Missed Lessons: Practicing Client-Led Litigation

    Author Photo

    New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.

  • Navigating 2025's Post-Grant Proceeding Shakeups

    Author Photo

    Extensive changes to the U.S. Patent Trial and Appeal Board's post-grant proceedings this year, including the new settled expectations factor and revitalization of Fintiv factors, require petitioners and patent owners alike to be mindful when selecting patents to assert and challenge, say attorneys at Quinn Emanuel.

  • Series

    The Law Firm Merger Diaries: How To Build On Cultural Fit

    Author Photo

    Law firm mergers should start with people, then move to strategy: A two-level screening that puts finding a cultural fit at the pinnacle of the process can unearth shared values that are instrumental to deciding to move forward with a combination, says Matthew Madsen at Harrison.

  • Latisse Ruling's Lessons On Avoiding Chemical Patent Pitfalls

    Author Photo

    The Federal Circuit's decision in Duke v. Sandoz, reversing a $39 million infringement claim for selling a generic Latisse product, reinforces a fundamental truth in chemical patent strategy: Broad genus claims rarely survive without clear evidence of possession of specific embodiments, says Kimberly Vines at Stites & Harbison.

  • Considerations When Invoking The Common-Interest Privilege

    Author Photo

    To successfully leverage the common-interest doctrine in a multiparty transaction or complex litigation, practitioners should be able to demonstrate that the parties intended for it to apply, that an underlying privilege like attorney-client has attached, and guard against disclosures that could waive privilege and defeat its purpose, say attorneys at DLA Piper.

  • Series

    The Law Firm Merger Diaries: Making The Case To Combine

    Author Photo

    When making the decision to merge, law firm leaders must factor in strategic alignment, cultural compatibility and leadership commitment in order to build a compelling case for combining firms to achieve shared goals and long-term success, says Kevin McLaughlin at UB Greensfelder.

  • Key Risks For Cos. As MAHA Influences Food Regulation

    Author Photo

    As the Make America Healthy Again movement alters state and federal legislative and regulatory priorities, measures targeting ultra-processed foods, front-of-package labeling requirements and restrictions on schools are creating new compliance and litigation risks for food and beverage manufacturers, pharmaceutical companies, retailers and digital advertisers, say attorneys at Kelley Drye.

  • State AGs May Extend Their Reach To Nat'l Security Concerns

    Author Photo

    Companies with foreign supply-chain risk exposure need a comprehensive risk-management strategy to address a growing trend in which state attorneys general use broadly written state laws to target conduct that may not violate federal regulations, but arguably constitutes a national security threat, say attorneys at Wiley.

  • Opinion

    Despite Deputy AG Remarks, DOJ Can't Sideline DC Bar

    Author Photo

    Deputy Attorney General Todd Blanche’s recent suggestion that the D.C. Bar would be prevented from reviewing misconduct complaints about U.S. Department of Justice attorneys runs contrary to federal statutes, local rules and decades of case law, and sends the troubling message that federal prosecutors are subject to different rules, say attorneys at HWG.

  • Key Strategies For Supplement Cos. Facing Lead Risks

    Author Photo

    In the wake of a recent Consumer Reports article detailing dangerously high levels of lead in many popular protein powders, supplement companies face increased litigation, rising enforcement risks and reputational harm — underscoring the need to monitor supply chains, test ingredients and understand labeling standards, say attorneys at Husch Blackwell.

  • From Bank Loans To Private Credit: Tips For Making The Shift

    Author Photo

    The relationship between private credit and syndicated bank deals will evolve as the private market continues to grow, introducing new challenges for borrowers comparing financing options, particularly pertaining to loan documentation and working capital, say attorneys at Haynes Boone.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.